-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
[Pharmaceutical Network Enterprise News] In order to cope with problems such as the imminent expiration of original research drugs, patent cliffs, intensified competition in the industry, and declining profits of generic drugs, many large pharmaceutical companies in recent years have begun to strengthen their research and development pipelines through continuous mergers and acquisitio.
Upcoming blockbuster drugs, complementary and synergistic scale effects of product portfolios,e.
According to incomplete statistics, in the first half of this year, there were 16 mergers and acquisitions of large pharmaceutical companies in the wor.
In addition, there are two companies recently rumored to have specific acquisition targe.
Among them, Pfizer initiated a total of 4 acquisitions in the first half of this year, accounting for one-fifth of the total acquisitions of large pharmaceutical companies in the first half of the ye.
It is understood that the transaction amount during the current year is relatively large, and the acquisitions worth over 10 billion US dollars (the acquisition of Biohaven for 16 billion US dollars) were won by Pfiz.
Specifically, on June 20, Pfizer announced that it had signed an equity subscription agreement with French vaccine company Valneva SE (VA.
US), agreeing to acquire French vaccine company Valneva at a price of 49 euros per share and a total consideration of 95 million euros 1% sta.
According to the Valneva website, the funds obtained from the Pfizer equity subscription agreement are mainly used to develop VLA15, a vaccine against Lyme disea.
It is understood that in the announcement, Pfizer also updated the terms of the cooperation and licensing agreement for the Lyme disease vaccine candidate VLA 1Under the revised partnership agreement, Valneva will bear 40% of the remaining co-development costs, up from 30% previous.
Pfizer will pay Valneva a 14%-22% royalty, up from 19% previous.
Additionally, royalties will pay Valneva up to $100 million based on cumulative sales
Other development and early commercialization expenses remain unchanged, with $168 million remaining, including a $25 million payment to Valneva after Pfizer initiated the Phase 3 stu.
On May 10, Pfizer and Biohaven Pharmaceuticals announced that the two companies had reached an agreement in which Pfizer agreed to acquire Biohaven Pharmaceuticals and its migraine drug Nurtec for a total of approximately $16 billi.
Pfizer will buy the biotech for $1450 per share (a 33% premium to its three-month average share price), giving it the rights to manufacture the migraine drug in the United Stat.
Biohaven is a commercial-stage biopharmaceutical company with innovative, first-in-class treatments to improve the lives of patients with debilitating neurological and neuropsychiatric disorders, including rare diseases, according to public informati.
On April 7, Pfizer announced that it will acquire ReViral for US$525 million and acquire the RSV treatment pipeline group of the latter, aiming to strengthen its research and development capabilities in the field of RSV treatment, and use ReViral’s expertise and drug candidates to solve the problems that have not been solved y.
Meeting the needs for RSV treatme.
At the heart of ReViral's RSV pipeline is the oral inhibitor Sisunadovir, which has FDA Fast Track designation and blocks RSV fusion with host cel.
Currently, another study aimed at inhibiting RSV replication by targeting the viral N protein is already in early testi.
On March 11, Pfizer announced that it had completed the acquisition of all outstanding shares, options and restricted stock units of Arena for $100 per share in cash, for a total equity value of approximately $7 billi.
Arena Pharmaceuticals is a clinical-stage company developing innovative potential therapies for the treatment of multiple immune-inflammatory diseases
For Pfizer's "buy, buy, buy" model, the industry believes that this is due to the fact that it is accelerating the expansion of other pipelines in the post-epidemic e.
In fact, it has launched a number of large-scale acquisitions last year, such as the acquisition of Trillium, a Canadian innovative drug developer for $26 billion, and the acquisition of biopharmaceutical company Arena for $7 billi.
It is worth mentioning that at the beginning of the year, Pfizer CEO Albert Bourla once said at the JPM conference that it will increase investment in small and medium-sized biotechnology companies, and there is no cap on mergers and acquisitio.
From this, it can be expected that Pfizer may have more big moves in the future in terms of mergers and acquisitio.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyo.
Upcoming blockbuster drugs, complementary and synergistic scale effects of product portfolios,e.
According to incomplete statistics, in the first half of this year, there were 16 mergers and acquisitions of large pharmaceutical companies in the wor.
In addition, there are two companies recently rumored to have specific acquisition targe.
Among them, Pfizer initiated a total of 4 acquisitions in the first half of this year, accounting for one-fifth of the total acquisitions of large pharmaceutical companies in the first half of the ye.
It is understood that the transaction amount during the current year is relatively large, and the acquisitions worth over 10 billion US dollars (the acquisition of Biohaven for 16 billion US dollars) were won by Pfiz.
Specifically, on June 20, Pfizer announced that it had signed an equity subscription agreement with French vaccine company Valneva SE (VA.
US), agreeing to acquire French vaccine company Valneva at a price of 49 euros per share and a total consideration of 95 million euros 1% sta.
According to the Valneva website, the funds obtained from the Pfizer equity subscription agreement are mainly used to develop VLA15, a vaccine against Lyme disea.
It is understood that in the announcement, Pfizer also updated the terms of the cooperation and licensing agreement for the Lyme disease vaccine candidate VLA 1Under the revised partnership agreement, Valneva will bear 40% of the remaining co-development costs, up from 30% previous.
Pfizer will pay Valneva a 14%-22% royalty, up from 19% previous.
Additionally, royalties will pay Valneva up to $100 million based on cumulative sales
Other development and early commercialization expenses remain unchanged, with $168 million remaining, including a $25 million payment to Valneva after Pfizer initiated the Phase 3 stu.
On May 10, Pfizer and Biohaven Pharmaceuticals announced that the two companies had reached an agreement in which Pfizer agreed to acquire Biohaven Pharmaceuticals and its migraine drug Nurtec for a total of approximately $16 billi.
Pfizer will buy the biotech for $1450 per share (a 33% premium to its three-month average share price), giving it the rights to manufacture the migraine drug in the United Stat.
Biohaven is a commercial-stage biopharmaceutical company with innovative, first-in-class treatments to improve the lives of patients with debilitating neurological and neuropsychiatric disorders, including rare diseases, according to public informati.
On April 7, Pfizer announced that it will acquire ReViral for US$525 million and acquire the RSV treatment pipeline group of the latter, aiming to strengthen its research and development capabilities in the field of RSV treatment, and use ReViral’s expertise and drug candidates to solve the problems that have not been solved y.
Meeting the needs for RSV treatme.
At the heart of ReViral's RSV pipeline is the oral inhibitor Sisunadovir, which has FDA Fast Track designation and blocks RSV fusion with host cel.
Currently, another study aimed at inhibiting RSV replication by targeting the viral N protein is already in early testi.
On March 11, Pfizer announced that it had completed the acquisition of all outstanding shares, options and restricted stock units of Arena for $100 per share in cash, for a total equity value of approximately $7 billi.
Arena Pharmaceuticals is a clinical-stage company developing innovative potential therapies for the treatment of multiple immune-inflammatory diseases
For Pfizer's "buy, buy, buy" model, the industry believes that this is due to the fact that it is accelerating the expansion of other pipelines in the post-epidemic e.
In fact, it has launched a number of large-scale acquisitions last year, such as the acquisition of Trillium, a Canadian innovative drug developer for $26 billion, and the acquisition of biopharmaceutical company Arena for $7 billi.
It is worth mentioning that at the beginning of the year, Pfizer CEO Albert Bourla once said at the JPM conference that it will increase investment in small and medium-sized biotechnology companies, and there is no cap on mergers and acquisitio.
From this, it can be expected that Pfizer may have more big moves in the future in terms of mergers and acquisitio.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyo.
